ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cholestyramine Resin

Also written as “Cholestyramine”, “cholestyramine” and “A3384”.

Its studies are mostly in Multiple Sclerosis · Hypercholesterolemia · Liver Cirrhosis, Biliary · Short Bowel Syndrome, led by 4 companies.

Drug pageCholestyramine Resin: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 23, 201310 company-led studies, 1 open or runningNext primary completion: May 16, 2031 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi61 open or runningphase 3since May 23, 2013May 23, 2013May 16, 2031phase 3 · NCT07930624
Ipsenits history only20 open or runningphase 2since Mar 3, 2014Mar 3, 2014none ahead
Eli Lillyits history only10 open or runningphase 1since Jun 6, 2023Jun 6, 2023none ahead
Pharmascienceits history only10 open or runningphase 2since Jul 26, 2019Jul 26, 2019none ahead

Also a collaborator on its studies: Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2013First study: phase 3 study in Multiple SclerosisFirst studyNCT01863888 · 70 enrolled · Belgium, Germany, Netherlands
  2. Jan 23, 2014Phase 1 study in Multiple SclerosisNCT02046629 · 12 enrolled · China
  3. Aug 31, 2016Phase 2 study in HypercholesterolemiaNCT02890992 · 42 enrolled · United States, Canada, Czechia and more
  4. Apr 18, 20182 phase 3 studies in HypercholesterolemiaNCT03510884, NCT03510715
  5. Nov 3, 2026Phase 3 study in Multiple SclerosisNCT07930624 · 2,500 planned

Ahead

  1. May 16, 2031Primary completion: phase 3 study in Multiple SclerosisNCT07930624

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07930624Multiple Sclerosis3Not yet recruitingMay 16, 20312,500
NCT03510884Hypercholesterolemia · United States, Argentina, Austria and more3CompletedJan 14, 2021153
NCT03510715Hypercholesterolemia · Brazil, Canada, Denmark and more3CompletedFeb 17, 202018
NCT02890992Hypercholesterolemia · United States, Canada, Czechia and more2CompletedSep 13, 201842
NCT02046629Multiple Sclerosis · China1CompletedJul 201412
NCT01863888Multiple Sclerosis · Belgium, Germany, Netherlands3CompletedJan 201570

How it is read

Names in the registry

  • “Cholestyramine”, 4 entries
  • “cholestyramine”, 3 entries
  • “A3384”, 1 entry
  • “CRC (A3384)”, 1 entry
  • “Questran”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.